Secondly, the requirement of KEAP1/Nrf2 pathway deregulation for sorafenib resistance in both parental and acquired resistant HCC cells provides a potential intervention target for future therapies. This evidence concerns the gene NFE2L2 and hepatocellular carcinoma.